In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 148 for your search:
Drug:  bortezomib
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SHCZH-2010-CT-001, NCT01249690

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Under 66
Sponsor: Other
Protocol IDs: PAD VS VCD Clinical Protocol, NCT01868828

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877

5.

Phase: Phase III
Type: Natural history/Epidemiology, Supportive care
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Version 1.1, NCT00872352

6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1005011049, X05324, NCT01146834

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-106, NCT01208662

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: HOVON 95 MM, 2009-017903-28, EMN02, NCT01208766

9.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P081226, NCT01208818

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Pro00001295, NCT01241708

11.

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: UAMS 2009-50, NCT01314625

12.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RHMCAN0749, NCT01324596

13.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA098543, NCT01371981

14.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000702425, EORTC-21082, EU-21116, EUDRACT-2009-011021-13, NCT01386398

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCL2005-01, NCT01449344

16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB06002, NCT01470131

17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2081-113, NCT01530594

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018751, 26866138-MMY-2073, NCT01539083

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number: 2009-010956-93, NCT01554852

20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-003, 2012-000128-16, NCT01568866

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: DSMM XIV, 2009-016616-21, NCT01685814

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-007, NCT01734928

23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ECWM-1, 2013-000506-37, NCT01788020

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2012-005, 2012-005283-97, NCT01818752

25.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: E1A11, NCI-2012-02608, U10CA021115, NCT01863550
1     
New Search